The US Food and Drug Administration has approved another vaccine to help protect older people from respiratory syncytial virus, known as RSV. The shot, made by Moderna and sold under the name of ...

The approval of Moderna's shot is based on a late-stage trial on older adults, who are more vulnerable to severe cases of RSV. The virus kills between 6,000 and 10,000 seniors every year and ...

Moderna’s messenger RNA vaccine for respiratory syncytial virus (RSV) is now FDA approved, a regulatory decision that comes nearly a year after GSK and Pfizer won regulatory approvals for their ...

Infectious disease experts say mRNA vaccines have been studied for decades, they are safe and effective, and were ...

The market for Moderna's RSV vaccine may be limited due to updated CDC recommendations. Moderna's oncology pipeline, including mRNA-4157/V940, shows promise but remains in the early stages.

The halt was triggered by an “imbalance,” the FDA said, in cases of severe lower respiratory tract infections (LRTIs) in children in a phase 1 trial of two Moderna RSV vaccines. One of the ...

NEW YORK, June 26 (Reuters) - Moderna Inc (MRNA.O), opens new tab respiratory syncytial virus (RSV) shot mRESVIA showed 50% efficacy in preventing RSV after 18 months, the drugmaker said on Wednesday.

The U.S. Food and Drug Administration approved Moderna’s vaccine to protect against respiratory syncytial virus, or RSV, a common virus that is among the leading causes of U.S. hospitalizations.

Moderna's vaccine was approved by the FDA for the prevention of RSV-associated lower respiratory tract disease in adults aged 60 or older. The company had previously said its vaccine could be used ...

Moderna’s shot is the third RSV vaccine for people 60 and older that’s gotten the green light from the FDA and the first mRNA vaccine among them. It’s the company’s second product to ...